

June 18, 2025
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer
(Securities Code: 4582)

Comprehensive Review of the Development of Brincidofovir for Diverse Indications Published by Wiley

SymBio Pharmaceuticals Limited today announced that an in-depth review of the development of brincidofovir has been featured as a chapter in the book², provides an overview of the history of the drug discovery process for brincidofovir (BCV), and Chimerix, Inc.'s achievement in securing U.S. approval¹ of the oral formulation of BCV to treat smallpox. The chapter also provides extensive coverage of SymBio's ongoing development of the intravenous formulation of brincidofovir (IV BCV) for its potential application in post-transplant viral infections, oncology, and neurodegenerative diseases.

BCV was discovered by Dr. Karl Hostetler, who at the time was a professor of infectious diseases at the University of California, San Diego. A lipid conjugate of cidofovir (CDV), BCV has broad antiviral activity against double-stranded DNA (dsDNA) viruses. BCV was identified as an optimal compound for further development after exploring various lipid conjugates, and BCV demonstrates >100 fold higher activity in vitro compared to CDV with significant improvements over CDV in oral bioavailability and safety.

Statement from Masatoshi Hazama, Corporate Officer and Chief Scientific Officer of SymBio Pharmaceuticals: "We are pleased that this comprehensive review offers readers valuable insight into BCV's unique characteristics, mechanisms of action, and its potential as a treatment for a diverse range of indications."

*1. [SymBio Press Release Announcing Chimerix's U.S. Approval of Oral BCV for Treatment of Smallpox](#)

*2. Authors: E. Randall Lanier, Scott Foster, Graciela Andre: Discovery and Development of Brincidofovir. Title of the Book: Trends in Antiviral Drug Development (2025, chapter.15 p447-500), editors: Michael J. Sofia, Zhengqiang Wang

Copyright © 2025 Wiley - VCH GmbH. All rights reserved, including rights for text and data mining and training of artificial intelligence technologies or similar technologies.

[Discovery and Development of Brincidofovir - Trends in Antiviral Drug Development - Wiley Online Library](#)